Benign Prostatic Hyperplasia Treatment Market

Benign Prostatic Hyperplasia Treatment Market by Type [Drug (Alpha Blockers(Tamsulosin, Doxazosin), 5-Alpha Reductase Inhibitors (Finasteride, Dutasteride), Surgical Treatment (TURP, TUMT, TUNA], End User (Hospitals) - Global Forecast to 2026

Report Code: MD 7836 Feb, 2021, by marketsandmarkets.com

[158 Pages Report] The benign prostatic hyperplasia treatment market is projected to reach USD 14.1 billion by 2026 from USD 10.8 billion in 2021, at a CAGR of 5.3% from 2021 to 2026. The presence of a large geriatric and target patient population and the improving healthcare infrastructure in several APAC countries are expected to offer growth opportunities in the benign prostatic hyperplasia treatment market during the forecast period.

Benign Prostatic Hyperplasia Treatment Market

To know about the assumptions considered for the study, Request for Free Sample Report

Covid -19 Impact On The Benign Prostatic Hyperplasia Treatment Market

The market for BPH treatment is anticipated to be considerably affected due to the outbreak of COVID-19. Since hospitals would face a huge demand for resources to fight against a possible increase of COVID-19 cases, elective surgeries of benign pathology had been recommended to be delayed until the strain on the hospital system from COVID-19 decreases. Owing to this, surgical procedures such as TURP, HoLEP, ThuLEP, and PVP had been postponed.

According to a recent study, nearly 2.5 million urological benign surgeries were estimated to be canceled during the peak of disruption by COVID-19. However, the number of alternative surgical procedures has increased. For instance, laser treatment can be adopted by additional surgery centers and other outpatient facilities not focused on COVID-19 patients.

Market Dynamics

DRIVER:Increasing prevalence of benign prostatic hyperplasia

BPH refers to the nonmalignant growth of prostate tissue and is a frequent cause of lower urinary tract symptoms among men. BPH is considered a normal part of male aging and is hormonally dependent on testosterone and dihydrotestosterone (DHT) production. Approximately 50% of men demonstrate histopathologic BPH by 60 years and 90% by 85 years.
Approximately 30 million men worldwide and 14 million men in the US are said to have BPH symptoms. (Source: WebMD LLC.).

Data from the Health Insurance Review and Assessment (HIRA) agency in 2018 revealed that nearly 7,600,000 patients were diagnosed with BPH in 2010, which increased by ~1.2 million in 2017. This represents an annual increase of about 7% and a total increase of 58% from 2010.

The growth of the aging population, especially the geriatric male segment, can be held as a prominent driver of BPH incidence, as BPH is a representative disease that appears in males during the aging process. As a result, the growth of this population segment will ensure demand for appropriate therapeutics in major markets. For example, China is believed to have the largest geriatric population; the population aged 65 years and above is estimated to account for 26.8% of its total population by 2050 from 10.1% in 2015 (Source: US Census Bureau). By 2050, the WHO estimates that there could be ~100 million people in China aged 80 years and above. In the UK, NHS data estimates that there were five million men in the country in 2019; this is expected to rise to 7 million in 2030 and nearly 9 million by the end of 2050.

RESTRAINTS:Side-effects associated with BPH medications

While drugs and surgery can treat BPH, both methods are associated with significant side-effects. Medicines commonly used to treat BPH include alpha-blockers, 5-ARIs (5-alpha reductase inhibitors), and other drug classes. Common side effects of alpha-blockers include dizziness, orthostatic hypotension, retrograde ejaculation, and rhinitis. Dizziness and orthostatic hypotension are of increased concern among the elderly as they can cause significant morbidities such as falls and subsequent injuries.

Finasteride and Dutasteride (among other 5-ARIs) convert testosterone to dihydrotestosterone. These drugs also reduce the synthesis of several neuroactive steroids, but the modulation of the neuroendocrine stress response may lead to depression. Other side effects of 5-ARIs are gynecomastia, impotence, and decreased libido, and ejaculate volume.

OPPORTUNITY: Promising Product Pipeline

The BPH treatment market offers considerable growth opportunities to manufacturers of generics. The patents of most medications for BPH treatment such as Avodart, Cialis, and Jalyn have expired, which has paved the way for generics. Besides, demand has also risen for more effective treatment options, resulting in a strong pipeline of products in the BPH market.

Studies reveal that price of a generic version of an alpha blocker is as low as USD 8 or less for a month’s supply, compared to nearly USD 100 per month for a branded product. While the lower price may affect overall revenue generated in the short term, it also translates into a far higher level of access that may lead to increased sales volumes overall.

Drug treatment is expected to hold the largest share of the benign prostatic hyperplasia treatment market, by type in 2021.

Based on the type, the BPH treatment market is segmented into drug treatment and surgical treatment. Drug treatment is the largest and the fastest-growing segment in this market. This can primarily be attributed to the use of medications as the first line of treatment among men with mild to moderate symptoms of BPH.

Home healthcare is expected to hold the largest share of the benign prostatic hyperplasia treatment market, in 2021.

Based on the end user, the market is segmented into home healthcare and hospitals & clinics. In 2019, home healthcare accounted for the largest share of this market, as most patients are prescribed medications over surgery. Patients are also advised to continue taking medications for a few weeks post-surgery and may even require catheters for a few days. As a result, the emphasis in his market is skewed toward home healthcare over hospital care.

Benign Prostatic Hyperplasia Treatment Market   by Region

North America commanded the largest share of the benign prostatic hyperplasia treatment market in 2021.

On the basis of region, the benign prostatic hyperplasia treatment market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. In 2019, North America commanded the largest share of the benign prostatic hyperplasia treatment market. The large share of this market segment can be attributed to the rising geriatric and obese population and the availability of research funding are the major factors driving the market growth. Initiatives by key players are also expected to contribute to the market.

Key Market Players

The major players operating in this market are Boston Scientific Corporation (US), Coloplast Group (Denmark), Teleflex Incorporated (US), Olympus Corporation (Japan), GlaxoSmithKline PLC (UK), Eli Lilly (US), Pfizer, Inc. (US), Abbott (US), Asahi Kasei Corporation (Japan), Merck & Co., Inc. (US), Astellas Pharma Inc. (Japan), Allergan plc (Ireland), Alembic (India), IPG Photonics Corporation (US), Richard Wolf GmbH (Germany), Unilab, Inc. (Philippines), Pharex Health Corporation (Philippines), Biolitec AG (Austria), Urologix, LLC (US), Advin Health Care (India), Medifocus, Inc. (Canada), Asclepion Laser Technologies GmbH (Germany), Pnn Medical A/S (Denmark), Surgical Lasers Inc. (Canada). Quanta Systems (Italy), Allium Ltd. (Israel), Lumenis Ltd. (Israel), KARL STORZ SE & Co. KG (Germany), and SRS Medical (US).

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market Size Available for Years

2018–2026

Base Year Considered

2019

Forecast Period

2021–2026

Forecast Units

Value (USD Billion)

Segments Covered

Type, end user and region

Geographies Covered

North America (US and Canada), Europe (Germany, France, UK, and the RoE), APAC (Japan, China, India, and the RoAPAC), and Rest of the World (RoW).

Companies Covered

Boston Scientific Corporation (US), Coloplast Group (Denmark), Teleflex Incorporated (US), Olympus Corporation (Japan), GlaxoSmithKline PLC (UK), Eli Lilly (US), Pfizer, Inc. (US), Abbott (US), Asahi Kasei Corporation (Japan), Merck & Co., Inc. (US), Astellas Pharma Inc. (Japan), Allergan plc (Ireland), Alembic (India), IPG Photonics Corporation (US), Richard Wolf GmbH (Germany), Unilab, Inc. (Philippines), Pharex Health Corporation (Philippines), Biolitec AG (Austria), Urologix, LLC (US), Advin Health Care (India), Medifocus, Inc. (Canada), Asclepion Laser Technologies GmbH (Germany), Pnn Medical A/S (Denmark), Surgical Lasers Inc. (Canada). Quanta Systems (Italy), Allium Ltd. (Israel), Lumenis Ltd. (Israel), KARL STORZ SE & Co. KG (Germany), and SRS Medical (US).

This research report categorizes the benign prostatic hyperplasia treatment market into the following segments and subsegments:

Benign Prostatic Hyperplasia Treatment Market by Type

  • Drug Treatment
    • Alpha Blockers
      • Alfuzosin
      • Doxazosin
      • Tamsulosin
      • Silodosin
      • Other Alpha Blockers
    • 5-Aplha Reductase Inhibitors
      • Finasteride
      • Dutasteride
    • Other Drug Classes
  • Surgical Treatment
    • Transurethral Resection of the Prostate (TURP)
    • Transurethral Microwave Thermotherapy (TUMT)
    • Transurethral Needle Ablation of the Prostate (TUNA)
    • Laser Therapy
    • Prostatic Stenting
    • UroLift Therapy
    • Rezϋm Therapy
    • Other Surgeries

    Benign Prostatic Hyperplasia Treatment Market, by Region

    • North America
      • US
      • Canada
    • Europe
      • Germany
      • UK
      • France
      • Rest of Europe
    • Asia Pacific
      • China
      • Japan
      • India
      • Rest of Asia Pacific

    Key developments:

    • In 2021, In January 2021, PHAREX Health Corporation in partnership with the Philippine Urological Association (PUA), launched Pharex Tamsulosin for BPH treatment.
    • In 2020, UroLift launched Advanced Tissue Control (ATC) System
    • In 2020, Asahi Kasei Pharma obtained Chinese approval for Flivas (naftopidil).
    • In 2019, Alembic received approval from the US FDA for its Abbreviated New Drug Application (ANDA) for Silodosin Capsules 4 mg and 8 mg
    • In 2018, NxThera’s Rezϋm system, a minimally invasive therapy (MIT) for patients with BPH, was included under Boston’s Urology and Pelvic Health business.
    • In 2017, Eli Lilly and Company entered into a settlement agreement with generic companies to resolve pending patent litigation.

    Frequently Asked Questions (FAQ):

    To speak to our analyst for a discussion on the above findings, click Speak to Analyst

  • TABLE OF CONTENTS

    1 INTRODUCTION (Page No. - 23)
        1.1 OBJECTIVES OF THE STUDY
        1.2 MARKET DEFINITION
               1.2.1 INCLUSIONS AND EXCLUSIONS
        1.3 MARKET SCOPE
               1.3.1 MARKETS COVERED
               1.3.2 YEARS CONSIDERED FOR THE STUDY
        1.4 CURRENCY
        1.5 STAKEHOLDERS
        1.6 LIMITATIONS OF THE CURRENT EDITION

    2 RESEARCH METHODOLOGY (Page No. - 27)
        2.1 RESEARCH DATA
               FIGURE 1 RESEARCH DESIGN
               2.1.1 SECONDARY DATA
                        2.1.1.1 Key data from secondary sources
               2.1.2 PRIMARY DATA
               FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,  AND REGION
                        2.1.2.1 Key data from primary sources
        2.2 MARKET SIZE ESTIMATION
               FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
               2.2.1 BOTTOM-UP APPROACH
               FIGURE 4 BPH TREATMENT MARKET: BOTTOM-UP APPROACH
               2.2.2 GROWTH FORECAST
               2.2.3 TOP-DOWN APPROACH
               FIGURE 5 BPH TREATMENT MARKET: TOP-DOWN APPROACH
        2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
               FIGURE 6 DATA TRIANGULATION METHODOLOGY
        2.4 ASSUMPTIONS FOR THE STUDY

    3 EXECUTIVE SUMMARY (Page No. - 35)
               FIGURE 7 BPH TREATMENT MARKET, BY TYPE, 2021 VS. 2026 (USD BILLION)
               FIGURE 8 BPH TREATMENT MARKET, BY END USER, 2021 VS. 2026 (USD BILLION)
               FIGURE 9 BPH TREATMENT MARKET, BY REGION, 2021 VS. 2026 (USD BILLION)

    4 PREMIUM INSIGHTS (Page No. - 37)
        4.1 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET OVERVIEW
               FIGURE 10 INCREASING PREVALENCE OF BPH IS THE MAJOR FACTOR DRIVING THE GROWTH OF THIS MARKET
        4.2 NORTH AMERICA: BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SHARE, BY TYPE (2020)
               FIGURE 11 DRUG TREATMENT TO DOMINATE THE NORTH AMERICAN MARKET IN 2020
        4.3 GEOGRAPHICAL SNAPSHOT OF THE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET
               FIGURE 12 JAPAN TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD

    5 MARKET OVERVIEW (Page No. - 39)
        5.1 INTRODUCTION
        5.2 MARKET DYNAMICS
               FIGURE 13 BPH TREATMENT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
               5.2.1 DRIVERS
                        5.2.1.1 Increasing prevalence of benign prostatic hyperplasia
               FIGURE 14 SHARE OF MALE POPULATION AGED 65 AND ABOVE, GLOBAL (2015-2019)
                        5.2.1.2 Increasing obesity
                        5.2.1.3 Rising preference for minimally invasive surgeries
                        5.2.1.4 Investments, funds, and grants for research in BPH treatment
                        5.2.1.5 Availability of reimbursement for surgeries
               TABLE 1 CPT CODES FOR BPH SURGERIES
               5.2.2 RESTRAINTS
                        5.2.2.1 Side-effects associated with BPH medications
               TABLE 2 SIDE-EFFECTS OF BPH DRUGS
               5.2.3 OPPORTUNITIES
                        5.2.3.1 Emerging markets
                        5.2.3.2 Promising product pipeline
               TABLE 3 PIPELINE DRUGS
               5.2.4 CHALLENGES
                        5.2.4.1 Low awareness regarding prostate health among men
                        5.2.4.2 Product recalls in the BPH treatment market
               TABLE 4 PRODUCT RECALLS IN THE BPH TREATMENT MARKET
        5.3 VALUE CHAIN ANALYSIS
               FIGURE 15 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASE
        5.4 SUPPLY CHAIN ANALYSIS
               FIGURE 16 DIRECT DISTRIBUTION—THE PREFERRED STRATEGY OF PROMINENT COMPANIES
        5.5 ECOSYSTEM ANALYSIS
               FIGURE 17 ECOSYSTEM ANALYSIS OF THE PHARMACEUTICAL INDUSTRY
               FIGURE 18 ECOSYSTEM ANALYSIS OF THE UROLOGY DEVICES MARKET
        5.6 REGULATORY SCENARIO
               5.6.1 PHARMACEUTICAL INDUSTRY
                        5.6.1.1 Regulatory requirements
                                   5.6.1.1.1 EU regulations
                                   5.6.1.1.2 US regulations
               5.6.2 MEDICAL DEVICES INDUSTRY
               TABLE 5 LIST OF REGULATORY AUTHORITIES
                        5.6.2.1 Regulatory requirements
                                   5.6.2.1.1 EU regulations
                                   5.6.2.1.2 US regulations
        5.7 AVERAGE SELLING PRICE TREND
               TABLE 6 AVERAGE SELLING PRICE OF BPH DRUGS
               TABLE 7 AVERAGE SELLING PRICE OF BPH TREATMENT PROCEDURES
               TABLE 8 AVERAGE SELLING PRICE OF DEVICES USED IN BPH TREATMENT PROCEDURES
        5.8 TECHNOLOGY ANALYSIS
        5.9 PESTLE ANALYSIS
        5.1 COVID-19 IMPACT ANALYSIS ON THE BPH TREATMENT MARKET
        5.11 EPIDEMIOLOGY OF BENIGN PROSTATIC HYPERPLASIA (2019)
               TABLE 9 BPH: COUNTRY-WISE PREVALENCE, 2019

    6 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY TYPE (Page No. - 56)
        6.1 INTRODUCTION
               TABLE 10 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY TYPE,  2018–2026 (USD MILLION)
        6.2 DRUG TREATMENT
               TABLE 11 BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
               TABLE 12 BPH DRUG TREATMENT MARKET, BY REGION, 2018–2026 (USD MILLION)
               6.2.1 ALPHA BLOCKERS
               TABLE 13 BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE,  2018–2026 (USD MILLION)
               TABLE 14 BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY REGION,  2018–2026 (USD MILLION)
                        6.2.1.1 Tamsulosin
                                   6.2.1.1.1 Tamsulosin has been prescribed for BPH since 2000
               TABLE 15 TAMSULOSIN MARKET, BY REGION, 2018–2026 (USD MILLION)
                        6.2.1.2 Silodosin
                                   6.2.1.2.1 Benefits of silodosin and launch of generics support market growth
               TABLE 16 SILODOSIN MARKET, BY REGION, 2018–2026 (USD MILLION)
                        6.2.1.3 Alfuzosin
                                   6.2.1.3.1 Side-effects and fewer generic launches have hindered market growth to some extent
               TABLE 17 ALFUZOSIN MARKET, BY REGION, 2018–2026 (USD MILLION)
                        6.2.1.4 Doxazosin
                                   6.2.1.4.1 Doxazosin was introduced in 2005 and has seen many generic launches since
               TABLE 18 DOXAZOSIN MARKET, BY REGION, 2018–2026 (USD MILLION)
                        6.2.1.5 Other alpha blockers
               TABLE 19 OTHER ALPHA BLOCKERS MARKET, BY REGION, 2018–2026 (USD MILLION)
               6.2.2 5-ALPHA REDUCTASE INHIBITORS
               TABLE 20 BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 21 BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY REGION, 2018–2026 (USD MILLION)
                        6.2.2.1 Dutasteride
                                   6.2.2.1.1 Availability of generics post-patent expiry support market growth
               TABLE 22 DUTASTERIDE MARKET, BY REGION, 2018–2026 (USD MILLION)
                        6.2.2.2 Finasteride
                                   6.2.2.2.1 Finasteride provides a range of benefits but is less effective than alpha blockers in improving LUTS
               TABLE 23 FINASTERIDE MARKET, BY REGION, 2018–2026 (USD MILLION)
               6.2.3 OTHER DRUG CLASSES
               TABLE 24 OTHER BPH DRUG CLASSES MARKET, BY REGION, 2018–2026 (USD MILLION)
        6.3 SURGICAL TREATMENT
               TABLE 25 BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 26 BPH SURGICAL TREATMENT MARKET, BY REGION, 2018–2026 (USD MILLION)
               6.3.1 TRANSURETHRAL RESECTION OF THE PROSTATE
                        6.3.1.1 TURP is the gold standard for BPH treatment
               TABLE 27 BPH SURGICAL TREATMENT MARKET FOR TURP, BY REGION, 2018–2026 (USD MILLION)
               6.3.2 LASER SURGERY
                        6.3.2.1 Evolution in lasers and high efficacy have supported the demand for laser surgery
               TABLE 28 BPH SURGICAL TREATMENT MARKET FOR LASER SURGERY, BY REGION,  2018–2026 (USD MILLION)
               6.3.3 TRANSURETHRAL MICROWAVE THERMOTHERAPY
                        6.3.3.1 TUMT has a lower risk of bleeding and requires no hospital stay, which has driven preference
               TABLE 29 BPH SURGICAL TREATMENT MARKET FOR TUMT, BY REGION, 2018–2026 (USD MILLION)
               6.3.4 UROLIFT THERAPY
                        6.3.4.1 Low rate of post-implantation surgical intervention indicates high effectiveness of UroLift and the potential for adoption
               TABLE 30 BPH SURGICAL TREATMENT MARKET FOR UROLIFT THERAPY, BY REGION,  2018–2026 (USD MILLION)
               6.3.5 TRANSURETHRAL NEEDLE ABLATION OF THE PROSTATE
                        6.3.5.1 Reimbursement coverage and growing preference for TUNA drive market growth
               TABLE 31 BPH SURGICAL TREATMENT MARKET FOR TUNA, BY REGION, 2018–2026 (USD MILLION)
               6.3.6 REZŪM THERAPY
                        6.3.6.1 The cost-effectiveness and efficacy of Rezūm water vapor therapy are driving demand for the procedure
               TABLE 32 BPH SURGICAL TREATMENT MARKET FOR REZŪM THERAPY, BY REGION,  2018–2026 (USD MILLION)
               6.3.7 PROSTATIC STENTING
                        6.3.7.1 Prostatic stenting is a temporary measure conducted under local anesthesia
               TABLE 33 BPH SURGICAL TREATMENT MARKET FOR PROSTATIC STENTING, BY REGION,  2018–2026 (USD MILLION)
               6.3.8 OTHER SURGERIES
               TABLE 34 OTHER BPH SURGICAL TREATMENTS MARKET, BY REGION, 2018–2026 (USD MILLION)

    7 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET,  BY END USER (Page No. - 73)
        7.1 INTRODUCTION
               TABLE 35 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY END USER,  2018–2026 (USD MILLION)
        7.2 HOME HEALTHCARE
               7.2.1 LARGE PATIENT POPULATION USING MEDICATIONS TO DRIVE THE GROWTH OF THE SEGMENT
               TABLE 36 BPH TREATMENT MARKET FOR HOME HEALTHCARE, BY REGION,  2018–2026 (USD MILLION)
        7.3 HOSPITALS & CLINICS
               7.3.1 RISING PREFERENCE FOR MINIMALLY INVASIVE SURGERIES TO DRIVE THE GROWTH OF THE SEGMENT
               TABLE 37 BPH TREATMENT MARKET FOR HOSPITALS & CLINICS, BY REGION,  2018–2026 (USD MILLION)

    8 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET,  BY REGION (Page No. - 77)
        8.1 INTRODUCTION
               TABLE 38 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY REGION,  2018–2026 (USD MILLION)
        8.2 NORTH AMERICA
               FIGURE 19 NORTH AMERICA: BPH TREATMENT MARKET SNAPSHOT
               TABLE 39 NORTH AMERICA: BPH TREATMENT MARKET, BY COUNTRY, 2018–2026 (USD MILLION)
               TABLE 40 NORTH AMERICA: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 41 NORTH AMERICA: BPH DRUG TREATMENT MARKET, BY CLASS,  2018–2026 (USD MILLION)
               TABLE 42 NORTH AMERICA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018, 2018–2026 (USD MILLION)
               TABLE 43 NORTH AMERICA: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE,  2018–2026 (USD MILLION)
               TABLE 44 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET, BY TYPE,  2018–2026 (USD MILLION)
               TABLE 45 NORTH AMERICA: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)
               8.2.1 US
                        8.2.1.1 The US holds the largest share of the North American market
               TABLE 46 US: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 47 US: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
               TABLE 48 US: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE,  2018–2026 (USD MILLION)
               TABLE 49 US: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 50 US: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 51 US: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)
               8.2.2 CANADA
                        8.2.2.1 Rising geriatric population and product approvals to support market growth
               TABLE 52 CANADA: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 53 CANADA: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
               TABLE 54 CANADA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE,  2018–2026 (USD MILLION)
               TABLE 55 CANADA: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 56 CANADA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 57 CANADA: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)
        8.3 EUROPE
               TABLE 58 EUROPE: BPH TREATMENT MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
               TABLE 59 EUROPE: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 60 EUROPE: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
               TABLE 61 EUROPE: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE,  2018–2026 (USD MILLION)
               TABLE 62 EUROPE: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 63 EUROPE: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 64 EUROPE: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)
               8.3.1 GERMANY
                        8.3.1.1 Increasing healthcare expenditure to support German market growth
               TABLE 65 GERMANY: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 66 GERMANY: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
               TABLE 67 GERMANY: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS,  BY TYPE, 2018, 2018–2026 (USD MILLION)
               TABLE 68 GERMANY: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 69 GERMANY: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 70 GERMANY: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)
               8.3.2 UK
                        8.3.2.1 Availability of innovative treatment options to drive the market in the UK
               TABLE 71 UK: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 72 UK: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
               TABLE 73 UK: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE,  2018–2026 (USD MILLION)
               TABLE 74 UK: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 75 UK: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 76 UK: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)
               8.3.3 FRANCE
                        8.3.3.1 Rising geriatric population to accelerate the growth of the market
               TABLE 77 FRANCE: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 78 FRANCE: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
               TABLE 79 FRANCE: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE,  2018–2026 (USD MILLION)
               TABLE 80 FRANCE: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 81 FRANCE: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 82 FRANCE: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)
               8.3.4 REST OF EUROPE
               TABLE 83 ROE: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 84 ROE: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
               TABLE 85 ROE: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018,  2018–2026 (USD MILLION)
               TABLE 86 ROE: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 87 ROE: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 88 ROE: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)
        8.4 ASIA PACIFIC
               FIGURE 20 ASIA PACIFIC: BPH TREATMENT MARKET SNAPSHOT
               TABLE 89 ASIA PACIFIC: BPH TREATMENT MARKET, BY COUNTRY, 2018–2026 (USD MILLION)
               TABLE 90 ASIA PACIFIC: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 91 ASIA PACIFIC: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
               TABLE 92 ASIA PACIFIC: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018, 2018–2026 (USD MILLION)
               TABLE 93 ASIA PACIFIC: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE,  2018–2026 (USD MILLION)
               TABLE 94 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 95 ASIA PACIFIC: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)
               8.4.1 JAPAN
                        8.4.1.1 Japan holds the largest share of the APAC market
               TABLE 96 JAPAN: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 97 JAPAN: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
               TABLE 98 JAPAN: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018,  2018–2026 (USD MILLION)
               TABLE 99 JAPAN: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 100 JAPAN: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 101 JAPAN: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)
               8.4.2 CHINA
                        8.4.2.1 Increasing obese population to support market growth
               TABLE 102 CHINA: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 103 CHINA: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
               TABLE 104 CHINA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018,  2018–2026 (USD MILLION)
               TABLE 105 CHINA: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 106 CHINA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 107 CHINA: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)
               8.4.3 INDIA
                        8.4.3.1 Rising prevalence of obesity to accelerate market growth in India
               TABLE 108 INDIA: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 109 INDIA: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
               TABLE 110 INDIA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018,  2018–2026 (USD MILLION)
               TABLE 111 INDIA: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 112 INDIA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 113 INDIA: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)
               8.4.4 REST OF ASIA PACIFIC
               TABLE 114 ROAPAC: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 115 ROAPAC: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
               TABLE 116 ROAPAC: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE,  2018–2026 (USD MILLION)
               TABLE 117 ROAPAC: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 118 ROAPAC: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 119 ROAPAC: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)
        8.5 REST OF THE WORLD
               TABLE 120 ROW: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 121 ROW: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
               TABLE 122 ROW: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018,  2018–2026 (USD MILLION)
               TABLE 123 ROW: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 124 ROW: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
               TABLE 125 ROW: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)

    9 COMPETITIVE LANDSCAPE & COMPANY PROFILES (Page No. - 112)
        9.1 COMPETITIVE LANDSCAPE
               9.1.1 OVERVIEW
               FIGURE 21 KEY DEVELOPMENTS IN THE BPH TREATMENT MARKET, JANUARY 2017–JANUARY 2021
               FIGURE 22 MARKET EVOLUTION FRAMEWORK: JANUARY 2017 TO JANUARY 2021
               9.1.2 MARKET SHARE ANALYSIS, 2019
                        9.1.2.1 BPH Drug Treatment Market Share Analysis, 2019
               FIGURE 23 BPH DRUG TREATMENT MARKET SHARE ANALYSIS, 2019
                        9.1.2.2 BPH Surgical Treatment Market Share Analysis, 2019
               FIGURE 24 BPH SURGICAL TREATMENT MARKET SHARE ANALYSIS, 2019
               9.1.3 COMPETITIVE SCENARIO
                        9.1.3.1 Product launches and approvals
               TABLE 126 KEY PRODUCT LAUNCHES & APPROVALS, JANUARY 2017−JANUARY 2021
                        9.1.3.2 Acquisitions
               TABLE 127 KEY ACQUISITIONS, JANUARY 2017−JANUARY 2021
                        9.1.3.3 Agreements and collaborations
               TABLE 128 KEY AGREEMENTS AND COLLABORATIONS, JANUARY 2017−JANUARY 2021
                        9.1.3.4 Expansions
               TABLE 129 KEY EXPANSIONS, JANUARY 2017−JANUARY 2021
                        9.1.3.5 Other developments
               TABLE 130 OTHER DEVELOPMENTS, JANUARY 2017−JANUARY 2021
               9.1.4 COMPANY EVALUATION MATRIX
                        9.1.4.1 Stars
                        9.1.4.2 Emerging Leaders
                        9.1.4.3 Pervasive Companies
                        9.1.4.4 Participants
               FIGURE 25 BPH TREATMENT MARKET: COMPANY EVALUATION MATRIX, 2019
               9.1.5 COMPETITIVE LEADERSHIP MAPPING (START-UPS AND SMES)
                        9.1.5.1 Progressive Companies
                        9.1.5.2 Starting Blocks
                        9.1.5.3 Responsive Companies
                        9.1.5.4 Dynamic Companies
               FIGURE 26 BPH TREATMENT MARKET: VENDOR DIVE MATRIX FOR SMES AND START-UPS, 2019
        9.2 COMPANY PROFILES
    (Business overview, Products offered, Recent Developments, MNM view)* 
               9.2.1 GLAXOSMITHKLINE
               FIGURE 27 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2019)
               9.2.2 ASTELLAS PHARMA
               FIGURE 28 ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2019)
               9.2.3 MERCK
               FIGURE 29 MERCK: COMPANY SNAPSHOT (2019)
               9.2.4 ELI LILLY AND COMPANY
               FIGURE 30 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2019)
               9.2.5 TELEFLEX INCORPORATED
               FIGURE 31 TELEFLEX INCORPORATED: COMPANY SNAPSHOT (2019)
               9.2.6 ABBOTT LABORATORIES
               FIGURE 32 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2019)
               9.2.7 BOSTON SCIENTIFIC CORPORATION
               FIGURE 33 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2019)
               9.2.8 PFIZER
               FIGURE 34 PFIZER: COMPANY SNAPSHOT (2019)
               9.2.9 OLYMPUS CORPORATION
               FIGURE 35 OLYMPUS CORPORATION: COMPANY SNAPSHOT (2019)
               9.2.10 ALEMBIC
               FIGURE 36 ALEMBIC: COMPANY SNAPSHOT (2019)
               9.2.11 ASAHI KASEI CORPORATION
               FIGURE 37 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2019)
               9.2.12 ALLERGAN
               FIGURE 38 ALLERGAN: COMPANY SNAPSHOT (2019)
               9.2.13 COLOPLAST GROUP
               FIGURE 39 COLOPLAST GROUP: COMPANY SNAPSHOT (2020)
               9.2.14 IPG PHOTONICS CORPORATION
               FIGURE 40 IPG PHOTONICS CORPORATION: COMPANY SNAPSHOT (2019)
               9.2.15 KARL STORZ SE & CO. KG
               9.2.16 RICHARD WOLF GMBH
               9.2.17 LUMENIS LTD.
               9.2.18 UNILAB, INC.
               9.2.19 PHAREX HEALTH CORP
               9.2.20 BIOLITEC AG
               9.2.21 UROLOGIX, LLC.
               9.2.22 ADVIN HEALTH CARE
               9.2.23 MEDIFOCUS INC.
               9.2.24 ASCLEPION LASER TECHNOLOGIES GMBH
               9.2.25 PNN MEDICAL A/S
               9.2.26 SURGICAL LASERS INC.
               9.2.27 QUANTA SYSTEM
               9.2.28 ALLIUM LTD
               9.2.29 SRS MEDICAL
    *Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies. 

    10 APPENDIX (Page No. - 150)
         10.1 INDUSTRY INSIGHTS
         10.2 DISCUSSION GUIDE
         10.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
         10.4 AVAILABLE CUSTOMIZATIONS
         10.5 RELATED REPORTS
         10.6 AUTHOR DETAILS

     

    The study involved four major activities to estimate the current size of the benign prostatic hyperplasia treatment market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.

    Secondary Research

    In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for this study.

    Primary Research

    Several stakeholders such as benign prostatic hyperplasia treatment manufacturers, vendors, distributors, researchers, and doctors from hospitals and clinics were consulted for this report. The demand side of this market is characterized by significant use of benign prostatic hyperplasia treatment due to , the increasing prevalence of benign prostatic hyperplasia, the rising preference for minimally invasive surgeries, increasing obesity rate, and investments, funds, and grants for research in the field of BPH. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

    Benign Prostatic Hyperplasia Treatment Market  Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the benign prostatic hyperplasia treatment market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The key players in the industry and markets have been identified through extensive secondary research
    • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

    Data Triangulation

    After arriving at the overall market size-using the market size estimation processes-the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and sub-segment, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the benign prostatic hyperplasia treatment industry.

    Report Objectives

    • To define, describe, and forecast the benign prostatic hyperplasia treatment market on the basis of type, end user, and region.
    • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, and opportunities, Covid-19 Impact Analysis)
    • To strategically analyse micromarkets with respect to individual growth trends, prospects, and contributions to the overall benign prostatic hyperplasia treatment market
    • To analyse market opportunities for stakeholders and provide details of the competitive landscape for key players
    • To forecast the size of the market segments in four geographical regions, namely, North America, Europe, the Asia Pacific, and Rest of the World.
    • To profile the key players and comprehensively analyse their product portfolios, market positions, and core competencies.
    • To track and analyse competitive developments such as product launches and approvals, partnerships, expansions, and acquisitions in the benign prostatic hyperplasia treatment market

    Available Customizations:

    With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

    Geographic Analysis:

    • Further breakdown of the benign prostatic hyperplasia treatment market into specific countries/regions in the Rest of Europe and the Rest of Asia Pacific.

    Company Information:

    • Detailed analysis and profiling of additional market players (up to 3) inclusive of:
    • Business Overview
    • Financial Information
    • Product Portfolio
    • Developments (last three years)
    COVID-19

    Get in-depth analysis of the COVID-19 impact on the Benign Prostatic Hyperplasia Treatment Market

    Benchmarking the rapid strategy shifts of the Top 100 companies in the Benign Prostatic Hyperplasia Treatment Market

    Request For Special Pricing
    Report Code
    MD 7836
    Published ON
    Feb, 2021
    Choose License Type
    BUY NOW
    • SHARE
    X
    Request Customization
    Speak to Analyst
    Speak to Analyst
    OR FACE-TO-FACE MEETING
    PERSONALIZE THIS RESEARCH
    • Triangulate with your Own Data
    • Get Data as per your Format and Definition
    • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
    • Any level of Personalization
    REQUEST A FREE CUSTOMIZATION
    LET US HELP YOU!
    • What are the Known and Unknown Adjacencies Impacting the Benign Prostatic Hyperplasia Treatment Market
    • What will your New Revenue Sources be?
    • Who will be your Top Customer; what will make them switch?
    • Defend your Market Share or Win Competitors
    • Get a Scorecard for Target Partners
    CUSTOMIZED WORKSHOP REQUEST
    ADJACENT MARKETS
    REQUEST BUNDLE REPORTS
    +1-888-600-6441
    • Call Us
    • +1-888-600-6441 (Corporate office hours)
    • +1-888-600-6441 (US/Can toll free)
    • +44-800-368-9399 (UK office hours)
    CONNECT WITH US
    ABOUT TRUST ONLINE
    ©2021 MarketsandMarkets Research Private Ltd. All rights reserved